Enhancing PET Signal at Target Tissue in Vivo:Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for Molecular Imaging of α<sub>v</sub>β<sub>3</sub> Integrin Expression with Gallium-68 by Imberti, Cinzia et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1021/acs.bioconjchem.6b00621
Link to publication record in King's Research Portal
Citation for published version (APA):
Imberti, C., Terry, S. Y. A., Cullinane, C., Clarke, F., Cornish, G. H., Ramakrishnan, N. K., ... Ma, M. T. (2017).
Enhancing PET Signal at Target Tissue in Vivo: Dendritic and Multimeric Tris(hydroxypyridinone) Conjugates for
Molecular Imaging of v3 Integrin Expression with Gallium-68. Bioconjugate Chemistry, 28(2), 481-495.
https://doi.org/10.1021/acs.bioconjchem.6b00621
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Enhancing PET Signal at Target Tissue in Vivo: Dendritic and
Multimeric Tris(hydroxypyridinone) Conjugates for Molecular
Imaging of αvβ3 Integrin Expression with Gallium-68
Cinzia Imberti,† Samantha Y. A. Terry,† Carleen Cullinane,‡,§ Fiona Clarke,∥ Georgina H. Cornish,∥
Nisha K. Ramakrishnan,† Peter Roselt,‡ Andrew P. Cope,∥ Rodney J. Hicks,‡,§ Philip J. Blower,†
and Michelle T. Ma*,†
†King’s College London, Division of Imaging Sciences and Biomedical Engineering, Fourth Floor Lambeth Wing, St Thomas’
Hospital, London SE1 7EH, United Kingdom
‡Peter MacCallum Cancer Centre, Melbourne, Victoria 3000, Australia
§Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia
∥King’s College London, Academic Department of Rheumatology, Centre for Molecular and Cellular Biology of Inﬂammation,
Faculty of Life Sciences and Medicine, London SE1 1UL, United Kingdom
*S Supporting Information
ABSTRACT: Tris(hydroxypyridinone) chelators conjugated to peptides
can rapidly complex the positron-emitting isotope gallium-68 (68Ga) under
mild conditions, and the resulting radiotracers can delineate peptide
receptor expression at sites of diseased tissue in vivo. We have synthesized a
dendritic bifunctional chelator containing nine 1,6-dimethyl-3-hydroxypyr-
idin-4-one groups (SCN-HP9) that can coordinate up to three Ga
3+ ions.
This derivative has been conjugated to a trimeric peptide (RGD3)
containing three peptide groups that target the αvβ3 integrin receptor.
The resulting dendritic compound, HP9-RGD3, can be radiolabeled in 97%
radiochemical yield at a 3-fold higher speciﬁc activity than its homologues
HP3-RGD and HP3-RGD3 that contain only a single metal binding site. PET
scanning and biodistribution studies show that [68Ga(HP9-RGD3)]
demonstrates higher receptor-mediated tumor uptake in animals bearing
U87MG tumors that overexpress αvβ3 integrin than [
68Ga(HP3-RGD)] and
[68Ga(HP3-RGD3)]. However, concomitant nontarget organ retention of [
68Ga(HP9-RGD3)] results in low tumor to nontarget
organ contrast in PET images. On the other hand, the trimeric peptide homologue containing a single tris(hydroxypyridinone)
chelator, [68Ga(HP3-RGD3)], clears nontarget organs and exhibits receptor-mediated uptake in mice bearing tumors and in mice
with induced rheumatoid arthritis. PET imaging with [68Ga(HP3-RGD3)] enables clear delineation of αvβ3 integrin receptor
expression in vivo.
■ INTRODUCTION
Peptide-based imaging agents in nuclear medicine have
tremendous utility in diagnosis, prognosis, and selection of
therapeutic regimes for patients. Radiometals can be incorpo-
rated into clinically relevant peptides via a bifunctional chelator,
providing eﬀective and sensitive radiotracers that can be
prepared conveniently in a radiopharmacy. The metallic isotope
68Ga possesses decay properties that are suitable for positron
emission tomography (PET) (68 min half-life, 1899 keV β+
emission with 88% abundance), and the availability of a
pharmaceutical grade 68Ge/68Ga generator means that the
number of molecular imaging agents based on 68Ga is likely to
increase in the coming years. The somatostatin receptor 2-
targeted imaging agent, 68Ga-DOTATATE for neuroendocrine
tumors,1−3 and more recently, the prostate speciﬁc membrane
antigen targeted conjugate, 68Ga-HBED-PSMA,4,5 have dem-
onstrated clinical utility in patient prognosis and management.
Other chelator systems have exhibited eﬃcient 68Ga3+ radio-
labeling properties, and the resulting radiolabeled conjugates
are eﬀective at delineating target tissue in vivo.6−12 Among
these are the tripodal tris(hydroxypyridinone) chelators
containing three 1,6-dimethyl-3-hydroxypyridin-4-one groups
that can coordinate radiometallic Ga3+ and Zr4+ ions,13−15 as
well as Fe3+ and Al3+ with high aﬃnity.16,17 Upon
deprotonation of hydroxyl groups, the hexadentate O6 ligand,
THP-Ac, can coordinate 68Ga3+ at mild pH (pH 6.5−7.5) and
low ligand concentrations (10 μM) in <5 min.13 Bifunctional
derivatives of THP-Ac can be attached to peptides, with the
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resulting conjugates able to rapidly and quantitatively
coordinate aqueous 68Ga3+ at room temperature at pH 5−
7.18,19
Multimeric peptide-based imaging agents that incorporate
more than one peptide targeting group (and in particular small
peptides that target the αvβ3 integrin receptor) have
demonstrated increased accumulation of activity at tissue
targets in vivo relative to their monomeric analogues, and are
eﬀective contrast agents.8,12,20−27 This increased accumulation
of radiotracer in the case of multimeric compounds can be
attributed to either (i) divalent binding, where two targeting
peptides bind to two receptors simultaneously, requiring
suﬃcient distance between the two intramolecular targeting
ligands to form this bridge; or (ii) an increased local eﬀective
concentration of targeting peptide at the receptor site, resulting
in a shift in equilibrium toward peptide receptor binding. In the
case where the multimeric derivative has an increased
persistence in the blood pool in vivo relative to the monomeric
derivative, it is also possible that increased uptake is a result of
increased bioavailability.
Dendritic and multimeric chelator systems for coordination
of Gd3+ and lanthanides provide enhanced contrast as MRI
agents compared to their single-chelator counterparts, in large
part due to the increased number of metal complexes
present.28−36 Multimeric constructs containing multiple chelat-
ing groups (including hydroxypyridinones) have also been
synthesized for the purposes of sequestering trace metal
ions.17,37 A small body of work has been described in which
the number of radiometal coordination sites on a radiolabeled
protein/antibody has been increased by incorporation of either
a dendrimer possessing multiple chelating groups,38−41 or a
pendant function (such as polylysine) on which multiple
chelators are appended.42−44 In these cases, the functionalized/
radiolabeled biomolecule retained aﬃnity for receptor targets in
vitro40,41,44 and in vivo.38,39,42,43 Additionally, when compared
to bioconjugates containing fewer chelating groups, dendrimer
or multichelator conjugated proteins demonstrated higher
speciﬁc activitythat is, a higher number of radionuclides
were bound per bioconjugate compared to homologues
containing a single chelator.38,41−43 In some cases, this resulted
in higher concentrations of radioactivity at target tissue
(tumors) in vivo.42
We are interested in using tris(hydroxypyridinone) ligands to
explore new ways of increasing accumulated radioactivity at
diseased tissue where target receptors are localized in vivo.
Here we aim to incorporate multiple in vivo targeting peptide
groups and multiple chelator groups into a single molecule,
thus increasing the aﬃnity of the radiolabeled conjugate for
receptors in vivo as well as increasing the speciﬁc activity of the
radiolabeled species itself. This approach mimics that of
multifunctionalized nanoparticles, where multiple copies of a
targeting biomolecule/modifying agent and multiple chelating
groups are appended to the surface of a nanoparticle.45−48 We
have employed the cyclic pentapeptide, c(RGDfK), (Chart 1)
that targets the endothelial αvβ3 integrin receptor expressed in
angiogenesis, and is associated with metastatic disease in
cancers. The biology of such conjugates is well understood, and
derivatives of c(RGDfK) are useful model compounds for
assessing novel approaches to molecular imaging using peptide-
based agents.
We have synthesized a novel bifunctional chelator construct
that incorporates three hexadentate tris(hydroxypyridinone)
metal binding sites for Ga3+ and an isothiocyanate group that
can be utilized as an attachment point to lysine residues of the
N-terminus of peptides. We have also employed a scaﬀold for
facile attachment of three c(RGDfK) peptide targeting groups
that contain available Lys or N-terminal primary amine groups,
ultimately providing a trimeric targeting motif. Conjugating
these two motifs together results in a dendritic compound
where an aryl group links a trimeric peptide targeting group and
three tris(hydroxypyridinone) (THP) groups. We have also
synthesized homologues of this compound to investigate the
Chart 1
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eﬀect of incorporating multiple copies of a peptide/chelating
group on in vitro uptake and in vivo biodistribution and target
tissue accumulation. Finally, we have chosen the radiotracer
with the best in vivo tumor to nontarget organ contrast and
assessed the radiotracer in a model of rheumatoid arthritis to
further illustrate the utility of 68Ga-labeled THP conjugates that
target integrin receptors for molecular imaging of in vivo
events.
■ RESULTS
Synthesis. To synthesize a multidentate chelator containing
nine 1,6-dimethyl-3-hydroxypyridin-4-one groups (as three
tris(hydroxypyridinone) moieties), the benzyl-protected tris-
(hydroxypyridinone) (2) (3 equiv) was reacted with tricarbox-
ylate (1), HATU, and diisopropylethylamine under microwave
conditions (Scheme 1). The resulting compound (3) was
puriﬁed using silica chromatography. Subsequent removal of
the phthalimide group furnished 4, which possesses a primary
amine that can be further functionalized for attachment to
biomolecules. This species was converted to a phenyl
isothiocyanate by reacting it with an excess of p-phenylene
diisothiocyanate, resulting in 5, which was isolated via
semipreparative reverse phase HPLC. Compound SCN-HP9
was obtained upon deprotection of the benzyl-protected
hydroxypyridinone groups by reaction of 5 with boron
trichloride in dichloromethane, followed by addition of
methanol.
This study aimed to assess a trimeric scaﬀold in which all
three peptide motifs are equidistant from the bifunctional
chelator and chemically equivalent to each other, thus ensuring
that all three motifs possess the same aﬃnity for the target
receptor. To achieve this, tricarboxylate 1 was converted to a N-
hydroxysuccinimide-activated intermediate (6) which was
reacted with 3 equiv of c(RGDfK), to provide the multimeric
compound 7. Compound 7 was puriﬁed and isolated using RP-
HPLC. The phthalimide group was removed by reaction with
hydrazine in ethanol, followed by addition of HCl (Scheme 2).
Subsequently, RGD3, which contains three c(RGDfK) peptide
groups and an apical primary amine, was isolated using RP-
HPLC.
Reaction of RGD3 with SCN-HP9 at 120 °C at 300 W in a
microwave reactor provided HP9-RGD3 (Chart 1) which was
puriﬁed and isolated using RP-HPLC in ≥95% purity. HP9-
RGD3 possesses three c(RGDfK) groups and three tris-
(hydroxypyridinone) groups, each attached through a tripodal
scaﬀold to a central phenyl group via thiourea linkages.
Similarly, the compound SCN-HP3 (Chart 1), synthesized as
previously described,18 was reacted with (i) RGD3 and (ii)
c(RGDfK) under the same microwave conditions. This
provided the derivatives HP3-RGD3 and HP3-RGD (Chart 1)
which are trimeric and monomeric c(RGDfK) homologues of
HP9-RGD3, the former two conjugates containing only a single
tris(hydroxypyridinone) ligand for coordination of a single
metal ion. These conjugates were also puriﬁed using RP-HPLC
and isolated in ≥95% purity (as previously reported for HP3-
RGD18).
Reaction of Hydroxypyridinone Derivatives with
68Ga3+/natGa3+. Solutions of HP9-RGD3, HP3-RGD3, and
HP3-RGD were added to an excess of
natGa(NO3)3. For each
of these solutions, the reverse phase LCMS total ion
chromatogram revealed Ga3+ complexation of the hydroxypyr-
idinone conjugates (Figure 1). As predicted, the conjugate HP9-
RGD3 that contains nine hydroxypyridinone groups (three
hexadentate tris(hydroxypyridinone) groups) coordinated three
Ga3+ metal ions, whereas the conjugates HP3-RGD3 and
HP3-RGD, each posses s ing on ly a s ing le t r i s -
(hydroxypyridinone) chelator, were bound to only a single
Ga3+ ion. In each case, the most intense set of peaks in the mass
Scheme 1. Synthesis of SCN-HP9
Scheme 2. Synthesis of RGD3
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spectrum (Figure 1) corresponding to this chromatographic
signal matched the stoichiometry of the complexes of formulas
listed in Table 1.
Solutions of 68Ga3+ produced from a 68Ge/68Ga generator
(80−120 MBq mL−1, 0.1 M HCl aqueous solution, 1 mL) were
added to HP9-RGD3, HP3-RGD3, and HP3-RGD and
immediately adjusted to pH 6 by addition of ammonium
acetate solution (1 M, 300 μL). As previously described,18,19
these radiolabeling reactions proceeded rapidly at room
temperature in less than 5 min, providing radiolabeled
conjugates in >98% radiochemical yield. These mixtures were
analyzed using the same HPLC conditions as those employed
for the above LCMS studies. Each reaction solution gave rise to
only a single signal in the radiochromatogram, each with a
similar retention time to corresponding LCMS chromatogram
signals (Figure 1, Table 1). Under these conditions, the
maximum occupancy of bioconjugate molecules by 68Ga3+ was
lowfor HP9-RGD3, maximum occupancy was <0.03%, and
for HP3-RGD3 or HP3-RGD, maximum occupancy was <0.01%.
To discern whether [Ga(HP9-RGD3)] could be chromato-
graphically distinguished from [Ga2(HP9-RGD3)] and
[Ga3(HP9-RGD3)], solutions of HP9-RGD3 were added to
aqueous solutions containing 1, 2, or 3 equiv of Ga3+, and the
samples were analyzed by reverse phase LCMS coupled to a
UV detector (Figure 2) using a less steep solvent gradient than
that employed above. [Note: To avoid confusion over the
oxidation state of the metal and the pH being monitored, we
adopt normal convention in showing peptides as neutral or
uncharged ligands either alone or in metal complexes, even
though Arg/R side chains are protonated in water at pH < 9,
and Asp/D side chains are deprotonated at pH > 5.
Additionally, we have elected not to indicate the protonation
state of HP groups in our nomenclature, even though at pH <
4.5 in water, HP groups are protonated bearing a single positive
charge, and >8 HP groups are deprotonated bearing a single
negative charge. At pH 5−7.5 in water, HP groups are neutral.
Upon coordination to a metal ion, each bidentate HP group is
deprotonated, formally bearing a single negative charge. Thus,
HP3 and HP9 groups and trivalent metal complexes thereof are
uncharged at pH 5−7.5 in aqueous solutions.] When an
analytical HPLC column was utilized for LCMS analysis, the
UV chromatogram of non-Ga-treated HP9-RGD3 revealed at
least three species (Figure 2b). The mass spectrum indicated
that these species corresponded to [Al(HP9-RGD3)], [AlFe-
(HP9-RGD3)], [Fe(HP9-RGD3)], and [Fe2(HP9-RGD3)]
(Figure 2b). It is likely that the metal ions that gave rise to
Figure 1. Radio-HPLC chromatogram of 68Ga-labeled peptide conjugates (bottom, black traces), and total ion count LCMS chromatograms of
natGa-complexed peptide conjugates acquired using the same mobile phase conditions (middle, blue traces); mass spectral signals associated with
each LCMS chromatographic signal (top, blackexperimental signal, redcalculated signal): (a) [Ga(HP3-RGD)], (b) [Ga(HP3-RGD3)], (c)
[Ga3(HP9-RGD3)].
Table 1. Observed and Calculated m/z Values for Mass Spectral Signals of [Ga(HP3-RGD)], [Ga(HP3-RGD3)], and [Ga3(HP9-
RGD3)], HPLC Retention Times of
nat/68Ga Labeled Conjugates, and Log D values of 68Ga Labeled Conjugates
compound
stoichiometry of observed MS
signal
observed (and calculated) m/z
(monoisotopic)
LCMS retention
time (min)
radio-HPLC retention
time (min)
log DOCT/PBS
(±SD)
[nat/68Ga(HP3-RGD)] C72H94N19O17S2Ga + 2H
+ 815.80 (815.80) 9.00 8.38 −2.62 ± 0.05
[nat/68Ga(HP3-RGD3)] C139H192N39O25S2Ga + 3H
+ 1034.45 (1034.45) 9.05 8.37 −2.23 ± 0.05
[natGa3/
68Ga(HP9-RGD3)] C226H306N57O59S2Ga3 + 4H
+ 1259.26 (1259.25) 8.88 8.32 −2.05 ± 0.19
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Figure 2. (a) Mass spectrum (right) of HP9-RGD3 acquired immediately after preparative HPLC puriﬁcation (without analytical HPLC separation).
Analytical HPLC UV chromatograms (left) and mass spectra (right) of solutions of HP9-RGD3 with (b) no added Ga
3+, (c) 1 equiv of Ga3+, (d) 2
equiv of Ga3+, (e) 3 equiv of Ga3+, (f) 68Ga generator eluate; (g) HPLC radiochromatogram (left) of [68Ga(HP9-RGD3)]. Charge of mass spectral
ions (z) = 4+.
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these complexes came from storage vials and/or parts of the
LCMS instrumentation, including the analytical reverse phase
C18 column. Notably, samples of HP9-RGD3 isolated
immediately after preparative HPLC that were not passed
through an analytical HPLC column, nor lyophilized and stored
for extended periods of time, contained fewer metal complex
species, as measured by mass spectrometry (Figure 2a),
although the [Al(HP9-RGD3)] complex was still prominent.
In solutions containing a single equivalent of Ga3+, the major
Ga-containing species corresponded to [Ga(HP9-RGD3)] and
[AlGa(HP9-RGD3)], and the corresponding UV chromato-
grams indicated the presence of multiple species (Figure 2c). In
solutions containing 2 equiv of Ga3+, several Ga-containing
species could be detected including [AlGa(HP9-RGD3)],
[FeGa(HP9-RGD3)], [Ga2(HP9-RGD3)], [AlFeGa(HP9-
RGD3)], [AlGa2(HP9-RGD3)], and [Fe2Ga(HP9-RGD3)]
(Figure 2d). Similarly, the corresponding UV chromatogram
indicated the presence of multiple species. Lastly, when 3 equiv
of Ga3+ were added to HP9-RGD3, only two Ga-containing
species were observed: [FeGa2(HP9-RGD3)] and [Ga3(HP9-
RGD3)] (Figure 2e). Only two signiﬁcant signals were
discernible in the UV chromatogram.
The same “slow” LCMS gradient coupled to UV detection
was used to analyze a sample nominally described here as
[68Ga(HP9-RGD3)] (Figure 2f,g). The concentration of
68Ga
was too low to allow detection of 68Ga-containing species using
the mass spectrometer available in our laboratory. The species
of lowest molecular weight most closely matched stoichiome-
tries of [AlFe(HP9-RGD3)], [Fe2(HP9-RGD3)], and [FeGa-
(HP9-RGD3)]. Unlike samples of HP9-RGD3, neither [Al(HP9-
RGD3)] nor [Fe(HP9-RGD3)] was detected. Generator eluate
is known to contain signiﬁcant amounts of Fe3+,49 and it is
likely that HP9-RGD3 complexes this during the radiolabeling
reaction. Indeed, unpublished data from our laboratory indicate
that concentrations of Fe, Al, and natGa in generator eluate (0.1
M HCl, from an Eckert and Ziegler generator) are
approximately 0.5 μM, 3 μM, and 1 μM, respectively. At
these concentrations, Fe3+, Al3+, and natGa3+ will compete with
68Ga3+ (present at picomolar concentrations) for ligand
coordination, accounting for low percentage occupancy by
68Ga3+ of all three conjugates. Most importantly, the radio-
labeled species in solution, referred to as [68Ga(HP9-RGD3)]
for the purposes of simple nomenclature, most likely
corresponds to [M2
68Ga(HP9-RGD3)] or [M
68Ga(HP9-
RGD3)] (M = Al, Fe, or
natGa). Thus, in vivo studies, described
herein, measure the biodistribution of 68Ga-labeled HP9-RGD3
in which one or two tris(hydroxypyridinone) sites are occupied
by nonradioactive metal ions. The resolution of the scintillation
detector was lower than the resolution of the UV detector, and
using the same gradient, the radiochromatogram of [68Ga(HP9-
RGD3)] gave rise to a single, very broad peak, coincident with
the UV chromatogram signals.
Signiﬁcantly higher amounts of 68Ga3+ were utilized to assess
the maximum speciﬁc activity that could be complexed
quantitatively by the conjugates. In this procedure, 68Ga3+
eluted from an iThemba generator was processed to
preconcentrate the generator eluate and remove 68Ge break-
through.50 The ﬁnal 68Ga3+ solution consisted of 700−1000
MBq 68Ga3+ in H2O/ethanol (82%/18%, with [HCl] = 0.18 M,
total volume = 1 mL). The conjugates HP9-RGD3, HP3-RGD3,
and HP3-RGD were added to this solution followed by
ammonium acetate and saline to obtain solutions (2.5 mL total
volume) at pH 5.5−6.5 that were suitable for in vivo
administration. Radiochemical yields of >97% were achieved
using a minimum of 4 nmol of HP9-RGD3 and 12 nmol of
either HP3-RGD3 or HP3-RGD. Decreasing the amount of
either HP3-RGD3 or HP3-RGD to 4 nmol decreased the
radiochemical yield (86% and 88%, respectively). Again, these
reactions proceeded rapidly (<5 min) at room temperature,
illustrating the utility of tris(hydroxypyridinone) chelators for
applications requiring rapid, kit-based labeling. The maximum
speciﬁc activity of 68Ga-labeled HP9-RGD3 (180−240 MBq
nmol−1) compared with that of HP3-RGD3 or HP3-RGD (60−
80 MBq nmol−1) was 3-fold higher. The maximum occupancy
by 68Ga3+ per molecule of bioconjugate was low in all cases. For
HP9-RGD3, maximum occupancy was <0.3%, and for HP3-
RGD3 or HP3-RGD, maximum occupancy was <0.1%.
Hydrophilicity of 68Ga-Radiolabeled Tracers, and
Aﬃnity for αvβ3 Integrin Receptor. The log DOCT/PBS
values of the 68Ga-labeled conjugates indicated that all three
radiotracers possess comparable hydrophilicity (Table 1), with
log D values all in the range of −2.7 to −2.0. These data are
consistent with the similar reverse-phase HPLC retention times
observed for all three radiotracers.
The half-maximal inhibitory concentration (IC50) values of
c(RGDfK), [Ga(HP3-RGD)], [Ga(HP3-RGD3)], and
[Ga3(HP9-RGD3)] were determined using a cell-free solid-
phase competitive binding assay with 125I-echistatin. Binding of
125I-echistatin to αvβ3 integrin was inhibited by all compounds
in a concentration-dependent manner broadly indicating that
[Ga(HP3-RGD)], [Ga(HP3-RGD3)], and [Ga3(HP9-RGD3)]
retained aﬃnity for αvβ3 integrin (Table 2, Figure S1). The IC50
value of [Ga(HP3-RGD)] (46 ± 16 nM) was comparable to
that of c(RGDfK) (28 ± 8 nM), demonstrating that
conjugation did not markedly aﬀect aﬃnity for the αvβ3
integrin receptor. However, the IC50 values of [Ga(HP3-
RGD3)] (73 ± 22 nM) and [Ga3(HP9-RGD3)] (79 ± 28 nM)
were higher than those of c(RGDfK) and [Ga(HP3-RGD)],
suggesting that, in this series of compounds, the presence of
three copies of c(RGDfK) peptide on a single molecule did not
impart higher aﬃnity toward αvβ3 integrin compared to the
monomeric THP derivative. This was surprising given that it
has been reported that other dimeric,22,23 trimeric,27 and
multimeric51 RGD peptides demonstrate higher aﬃnities for
αvβ3 integrin than their monomeric homologues. The addition
of the dendritic HP9 chelator did not aﬀect aﬃnity of RGD3 for
αvβ3 integrinIC50 values of [Ga3(HP9-RGD3)] and
[Ga3(HP3-RGD3)] were very similar.
Biodistribution of 68Ga-Labeled RGD Conjugates. The
biodistribution of [68Ga(HP9-RGD3)], [
68Ga(HP3-RGD3)], and
[68Ga(HP3-RGD)] was assessed in Balb/c nu/nu mice bearing
αvβ3 integrin-positive glioblastoma U87MG tumors (n = 3).
Table 2. IC50 Values for c(RGDfK), [Ga(HP3-RGD)],
[Ga(HP3-RGD3)], and [Ga3(HP9-RGD3)], Determined
Using a Solid-Phase Competitive Binding Assay with 125I-
Echistatin
compound
IC50 (nM) (±standard
error)
95% conﬁdence interval
(nM)
c(RGDfK) 28 ± 8 12−45
[Ga(HP3-RGD)] 46 ± 16 13−79
[Ga(HP3-RGD3)] 73 ± 22 30−116
[Ga3(HP9-
RGD3)]
79 ± 28 23−134
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Each animal was administered 18−33 MBq of 68Ga-labeled
tracer and PET scanned at either 1 or 2 h post-injection (PI)
for 10 min, followed immediately by euthanasia and organ
harvesting for ex vivo radioactivity counting. To assess
speciﬁcity of each radiotracer, a separate group of animals
was coadministered c(RGDfK) (0.4 mg per animal) with the
tracer, followed by scanning, euthanasia, and ex vivo organ
counting 1 h PI.
Ex vivo biodistribution data (Figures 3 and S2, and Tables 3,
4, and S1) demonstrated that tumor uptake of dendritic
[68Ga(HP9-RGD3)] was 1.75-fold higher than that of
monomeric [68Ga(HP3-RGD)] at 1 h PI. Tumor uptake of
trimeric [68Ga(HP3-RGD3)] was 1.49-fold higher than that of
[68Ga(HP3-RGD)]. Tumor uptake of [
68Ga(HP9-RGD3)] was
higher than that of [68Ga(HP3-RGD3)], but this was not
statistically signiﬁcant. By 2 h PI, there were no diﬀerences in
normalized tumor uptake between the three tracers.
Animals administered [68Ga(HP9-RGD3)] showed increased
persistence of activity in blood, and increased liver, spleen,
muscle, and lung accumulation compared to animals adminis-
tered either [68Ga(HP3-RGD3)] or [
68Ga(HP3-RGD)] at both
1 and 2 h PI (Figure 3, Table S1). At both 1 and 2 h PI, the
concentration of kidney activity for animals administered
[68Ga(HP9-RGD3)] (1 h PI, 28.32 ± 3.76%ID g
−1) was
considerably higher than that of animals administered [68Ga-
(HP3-RGD3)] (1 h PI, 10.73 ± 0.18%ID g
−1), which in turn
was higher than that of animals administered [68Ga(HP3-
RGD)] (1 h PI, 4.91 ± 0.74%ID g−1).
Additionally, ex vivo biodistribution data (Figures 3 and S2,
Table 3) for all three tracers demonstrated that tumor uptake
was target-speciﬁc at 1 h PI, with signiﬁcantly lower tumor
uptake for animals coadministered c(RGDfK) (“blocked”
groups). In the blocked groups for all three tracers, uptake in
lungs, heart, spleen, and muscle was generally lower than that
observed in “nonblocked” groups. This is consistent with
previous reports of receptor-mediated uptake of αvβ3 integrin
targeted radiotracers,18,22,25,27 and with the expression of αvβ3
integrin at low levels in normal vasculature tissue.52,53 For all
three tracers, radioactivity concentration in the kidneys was
higher for the blocked groups than for the nonblocked groups.
Similar patterns have previously been described for RGD
peptide conjugates,11 and have been attributed to slower kidney
ﬁltration rates in the presence of larger amounts of peptide.
PET imaging data for all three tracers was consistent with ex
vivo biodistribution data. In PET scans of all three radiotracers
acquired 1 h PI, tumors could be delineated, whereas in PET
scans of animals coadministered c(RGDfK), tumors could not
be delineated (Figure 3). Concentration of radioactivity in
kidneys and livers for animals administered [68Ga(HP9-RGD3)]
was signiﬁcantly higher than that of animals administered either
[68Ga(HP3-RGD3)] or [
68Ga(HP3-RGD)].
Thus, although tumor uptake of dendritic [68Ga(HP9-
RGD3)] was higher at 1 h PI than that of either [
68Ga(HP3-
RGD3)] or [
68Ga(HP3-RGD)], high nontarget organ uptake of
[68Ga(HP9-RGD3)] rendered tumor to nontarget organ ratios
signiﬁcantly lower than that of either [68Ga(HP3-RGD3)] or
Figure 3. (a) Ex vivo biodistribution of mice bearing αvβ3 integrin-
positive U87MG tumors administered (a-i) [68Ga(HP3-RGD)], (a-ii)
[68Ga(HP3-RGD3)], and (a-iii) [
68Ga(HP9-RGD3)], 1 and 2 h PI, and
1 h PI of coadministered c(RGDfK) (blocked); n = 3. Error bars
correspond to standard error of the mean. (b) Representative PET
maximum intensity projections of Balb/c nu/nu mice bearing a
U87MG tumor on right ﬂanks at 1 h PI of (b-i) [68Ga(HP3-RGD)],
(b-ii) [68Ga(HP3-RGD)] + c(RGDfK), (b-iii) [
68Ga(HP3-RGD3)], (b-
iv) [68Ga(HP3-RGD3)] + c(RGDfK), (b-v) [
68Ga(HP9-RGD3)], and
(b-vi) [68Ga(HP9-RGD3)] + c(RGDfK). Red arrow indicates position
of tumors on animals.
Table 3. αvβ3 Integrin-Positive U87MG Tumor Uptake as Measured by Ex Vivo Biodistribution, 1 h PI, and 1 h PI of
Coadministered c(RGDfK) (Blocked); n = 3
compound 1 h PI, %ID g‑1 (±SEM) with block, 1 h PI, %ID g‑1 (±SEM) mean diﬀerence (95% CI), %ID g‑1 p value
[68Ga(HP3-RGD)] 2.86 ± 0.43 0.99 ± 0.12 1.88 (0.86−2.90) 0.0069
[68Ga(HP3-RGD3)] 4.28 ± 0.53 0.98 ± 0.14 3.29 (2.04−4.54) 0.0019
[68Ga(HP9-RGD3)] 4.69 ± 0.35 1.17 ± 0.11 3.52 (2.68−4.37) 0.0003
Table 4. Diﬀerences in Tumor Uptake of 68Ga-Tracers 1 h
PI, as Measured by Ex Vivo Biodistribution
comparison mean diﬀerence 1 h PI (95% CI), %ID g‑1 p value
[68Ga(HP3-RGD)]
and
[68Ga(HP3-RGD3)]
1.42 (−0.14−2.97) 0.065
[68Ga(HP3-RGD)]
and
[68Ga(HP9-RGD3)]
1.83 (0.56−3.10) 0.016
[68Ga(HP3-RGD3)]
and
[68Ga(HP9-RGD3)]
0.41 (−1.04−1.86) 0.473
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[68Ga(HP3-RGD)] at 1 h PI. Contrast between tumor and
nontarget organs was best achieved with [68Ga(HP3-RGD3)]
(Figure S3); therefore, further imaging studies assessing αvβ3
integrin expression in a mouse model of rheumatoid arthritis
utilized this tracer.
Imaging Arthritis with [68Ga(HP3-RGD3)]. To demon-
strate the broad utility of tris(hydroxypyridinone) conjugates
for molecular imaging of αvβ3 integrin receptor expression,
[68Ga(HP3-RGD3)] was used to image synovial inﬂammation in
mice with induced rheumatoid arthritis. The αvβ3 integrin
receptor is associated with cell types that are involved in
rheumatoid arthritis at synovial joints, including bone resorbing
osteoclasts, activated macrophages, and angiogenic endothelial
cells.53,54 Previous studies have demonstrated that radiolabeled
RGD peptides target arthritic tissue55−57 as well as
osteoclasts.58
In these experiments, [68Ga(HP3-RGD3)] (8−13 MBq) was
administered to healthy mice (C57Bl/6 male 6−8 week mice),
and mice with induced mild and severe rheumatoid
arthritis.59,60 A separate group of animals with severe
rheumatoid arthritis was administered both [68Ga(HP3-
RGD3)] and an excess of c(RGDfK) to assess speciﬁcity of
in vivo targeted accumulation. Prior to induction of arthritis
and administration of radiotracer, the diameters of wrist and
ankle joints of all animals were measured using calipers to score
the severity of arthritis. At 1 h PI of radiotracer, animals were
euthanized by CO2 asphyxiation followed by PET scanning and
organ collection for ex vivo biodistribution.
For all animals, radioactivity concentrations in nontarget
tissues and organs, as determined by ex vivo biodistribution
data (Figure S4), were consistent with results obtained from
animals bearing U87MG tumors administered the same
radiotracer. Blockade studies with c(RGDfK) in rheumatoid
arthritis animals also indicated that some localization of
[68Ga(HP3-RGD3)] in all harvested organs except the kidneys
was likely to be receptor-mediated (Table S2).
The ex vivo biodistribution data demonstrated that the
amount of radioactivity in severely arthritic joints (increase in
wrist and ankle diameter >0.5 mm) was higher than that in
joints of healthy animals, or in joints of animals with mild
arthritis (increase in wrist and ankle diameter <0.5 mm). In this
analysis, joints were grouped according to their type (wrist or
ankle) and the increase in swelling (caliper joint measure-
ments) from point of disease induction to the point of imaging
(8 days). Total %ID is reported rather than %ID g−1, because of
the large experimental error associated with dissecting and
measuring the mass of mouse joint tissue. In severely arthritic
joints, there was signiﬁcantly higher radioactivity accumulation
than in joints that were not classiﬁed as severely arthritic
(including healthy animals and animals induced with mild
arthritis) (Figure 4, Table 5). On the basis of %ID, severely
arthritic joints could be diﬀerentiated from healthy joints, or
joints that did not exhibit severe inﬂammation. Furthermore,
blockade studies in severely arthritic animals demonstrated that
uptake of [68Ga(HP3-RGD3)] in inﬂamed arthritic joints was
receptor-mediated (Figure 4, Table 5). Joint uptake in severely
arthritic animals coadministered [68Ga(HP3-RGD3)] and
c(RGDfK) peptide was signiﬁcantly lower than that of severely
arthritic animals administered solely [68Ga(HP3-RGD3)].
When animals’ joints were grouped according to extent of
disease (classiﬁed according to whether animals were induced
with mild or severe arthritis rather than increase in joint
swelling), there were no statistically signiﬁcant diﬀerences in
joint uptake between healthy mice and mice with mild arthritis.
There were statistically signiﬁcant diﬀerences between healthy
mice and mice with severe arthritis, and between mice with
mild arthritis and those with severe arthritis (Figure S5, Table
S3).
PET scans were consistent with biodistribution data (Figure
5). In PET images acquired 1 h PI, severely arthritic joints
could be distinguished from joints that were not inﬂamed, both
Figure 4. Ex vivo biodistribution of arthritic joints of healthy mice
(blue), mice with induced mild rheumatoid arthritis (red) and mice
with induced severe rheumatoid arthritis (green), administered
[68Ga(HP3-RGD3)] (8−13 MBq). A blockade study was also
undertaken in mice with induced severe rheumatoid arthritis, in
which [68Ga(HP3-RGD3)] was coadministered with cRGDfK (pink).
Top: %ID in feet/ankle joints; bottom: %ID in hand/wrist joints.
Increase in swelling of joints was measured as the increase from the
point of induction of arthritis to PET scanning/biodistribution studies
(8 days).
Table 5. Ex Vivo Biodistribution of Joints of Mice
Administered [68Ga(HP3-RGD3)]
group
%ID 1 h PI
(±SEM)
mean diﬀerence (95% CI)
compared to severely
arthritic joints, %ID p value
Wrists
severely arthritic
(>0.5 mm
increase)
0.26 ± 0.02 - -
severely arthritic
with block
0.08 ± 0.01 0.18 (0.16−0.20) <0.0001
healthy or mildly
arthritic (<0.5
mm increase)
0.14 ± 0.02 0.12 (0.09−0.14) <0.0001
Ankles
severely arthritic
(>0.5 mm
increase)
0.68 ± 0.18 - -
severely arthritic
with block
0.24 ± 0.02 0.44 (0.27−0.63) 0.0005
healthy or mildly
arthritic (<0.5
mm increase)
0.29 ± 0.03 0.39 (0.30−0.50) <0.0001
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.6b00621
Bioconjugate Chem. 2017, 28, 481−495
488
between diﬀerent animals (Figure 5a vs b) and within the same
animal (Figure 5b). For example, within one animal with severe
arthritis, the left wrist was severely inﬂamed (a 1 mm increase
in swelling from the point of disease induction) but the right
demonstrated no swelling throughout the disease induction
period. In the PET/CT scan, higher radiotracer uptake was
discernible in the left wrist compared to the right wrist (Figure
5b), consistent with ex vivo biodistribution data.
■ DISCUSSION AND CONCLUDING REMARKS
Multimeric receptor-targeted radiolabeled agents, in which each
molecule contains either multiple copies of each targeting
peptide, or multiple copies of a multidentate chelator,42 can
deliver increased radioactive payloads to target tissue relative to
monomeric homologues. Dimeric,25,61−63 trimeric,8,27 tetra-
meric,64,65 and octameric66 RGD conjugates radiolabeled with
metallic PET isotopes have demonstrated eﬃcacious αvβ3
integrin targeting in vivo. Herein, we have described the ﬁrst
radiolabeled molecular compound that integrates multiple
copies of a chelator and multiple copies of peptide, in this
case, αvβ3 integrin-targeted c(RGDfK). In contrast to previous
work on multimeric RGD peptide conjugates, the new dendritic
system possesses tris(hydroxypyridinone) chelators that coor-
dinate 68Ga3+ quantitatively at ambient temperature, near
neutral pH, and micromolar concentrations of conjugate,
allowing for rapid, one-step labeling.
Synthesis of HP9-RGD3, which consists of a bifunctional
enneakis(hydroxypyridinone) ligand attached to a trimeric
peptide targeting αvβ3 integrin receptors, enabled assessment of
whether dendritic chelator systems could enhance speciﬁc
activity in radiolabeled molecular imaging agents. Incorporation
of multiple hexadentate tris(hydroxypyridinone) groups into a
single construct, HP9-RGD3, increased speciﬁc activity relative
to HP3 derivatives. At concentrations of ∼1.6 μM, near-
quantitative radiochemical yields (>97%) were achieved for
HP9-RGD3, whereas for HP3-RGD and HP3-RGD3, concen-
trations of 5 μM were required to achieve the same
radiochemical yields. The maximum speciﬁc activity of 68Ga-
labeled HP9-RGD3 (180−240 MBq nmol−1) was 3-fold higher
when compared with that of HP3-RGD3 or HP3-RGD (60−80
MBq nmol−1).
Analytical HPLC using a UV detector (interfaced with a mass
spectrometer and a gamma scintillation detector) could
distinguish numerous signals arising from a sample of
[68Ga(HP9-RGD3)]. For the same sample, line widths of
signals in the radiochromatogram and the TIC chromatograms
were much broader, and could not be precisely correlated with
individual signals in the UV chromatogram. Mass spectral
analysis indicated that all tris(hydroxypyridinone) sites in
[68Ga(HP9-RGD3)] were likely occupied by trivalent metal
ions. Hexadentate THP-Ac has a very high aﬃnity for Fe3+,
with log K1 = 32.52 and pFe
3+ = 28.47 at pH 7.4 ([Fe3+] = 10−6
M, [Ligand] = 10−5 M).17 Dendritic derivatives have similar
aﬃnities.17 While aﬃnities of 3-hydroxy-4-pyridinones for Al3+
are normally several orders of magnitude lower than for Fe3+,
they are still highfor example, for a series of tripodal
tris(hydroxypyridinones), pAl3+ consistently measured 21−22
at pH 7.4.16 It is unsurprising that in 68Ga-labeled HP9-RGD3,
tris(hydroxypyridinone) sites unoccupied by 68Ga3+ complex
adventitious Fe3+, Al3+, and natGa3+.
It was hypothesized that the higher speciﬁc activity and the
trimeric peptide nature of [68Ga(HP9-RGD3)] might result in
targeted tumor delivery of a comparatively higher radioactive
payload per molecule of receptor-bound bioconjugate com-
pared to [68Ga(HP3-RGD3)] and [
68Ga(HP3-RGD)].
Despite the lower IC50 value of the monomeric [
68Ga(HP3-
RGD)] species, its in vivo normalized tumor accumulation (as
measured by ex vivo biodistribution) was lower than that of
trimeric [68Ga(HP3-RGD3)] and dendritic [
68Ga(HP9-RGD3)]
at 1 h PI (Figure 3). The radiotracers’ pharmacokinetics as well
as αvβ3 integrin aﬃnities are likely to be important in
inﬂuencing their relative tumor uptake. It is possible that in
vivo, blood clearance of [68Ga(HP3-RGD)] was faster than that
of [68Ga(HP3-RGD3)] and [
68Ga(HP9-RGD3)] at early time
points (before 1 h PI), resulting in higher tumor bioavailability
and thus higher uptake of [68Ga(HP3-RGD3)] and [
68Ga(HP9-
RGD3)] 1 h PI. Additionally, for HP9-RGD3, it is likely that
there was comparatively lower occupancy of target αvβ3 integrin
in vivo by unlabeled conjugate. Comparable amounts of
radioactivity were administered to each mouse for the three
diﬀerent radiotracers, but in the case of HP9-RGD3, ∼0.15
nmol of conjugate was administered to each animal, compared
to ∼0.5 nmol for HP3-RGD3 and HP3-RGD.
There was an increase in radioactivity concentration in
tumors at 1 h PI for [68Ga(HP9-RGD3)] compared to
[68Ga(HP3-RGD3)] (mean diﬀerence = 0.41%ID g
−1), and
for [68Ga(HP3-RGD3)] compared to [
68Ga(HP3-RGD)] (mean
diﬀerence = 1.42%ID g−1) (Tables 3, 4). There was a
statistically signiﬁcant increase (mean diﬀerence = 1.83%ID
g−1) in tumor accumulation at 1 h PI for [68Ga(HP9-RGD3)]
compared to [68Ga(HP3-RGD)]. Thus, the combination of
increased speciﬁc activity and a multimeric eﬀect could be
responsible for this increase in radioactivity concentration in
tumors of animals administered the dendritic radiotracer. Such
an observation lends credence to the hypothesis that dendritic
radiotracers that incorporate multiple chelating groups and
copies of targeting peptides can increase radioactive payload at
tissue, relative to monomeric homologues. The higher mean
diﬀerence in tumor uptake between [68Ga(HP3-RGD3)] and
[68Ga(HP3-RGD)], compared to [
68Ga(HP9-RGD3)] and
[68Ga(HP3-RGD3)], suggests that the presence of a multimeric
peptide is the more signiﬁcant of the two factors in enhancing
tumor uptake.
The distance between c(RGDfK) groups in HP3-RGD3 and
HP9-RGD3 is not suﬃcient to allow simultaneous binding to
two or more αvβ3 integrin receptors. It is possible that
Figure 5. PET/CT maximum intensity projections of mice
administered [68Ga(HP3-RGD3)] (8−13 MBq) 1 h PI (all PET
images scaled from 0.08 to 8.0%ID g−1): (a) a healthy C57Bl/6
mouse; (b) a C57Bl/6 mouse with severe rheumatoid arthritis; (c) a
C57Bl/6 mouse with severe rheumatoid arthritis coadministered
c(RGDfK). Arrows indicate joints with an increase in swelling >0.5
mm.
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increasing this distance to allow simultaneous binding could
result in higher uptake and retention in tissue that over-
expresses αvβ3 integrin receptors.
62,63
We have previously demonstrated that THP peptide
conjugates can rapidly and quantitatively complex 68Ga3+ at
near-neutral pH, ambient temperature, and low chelator
concentrations, and that the resulting radiotracers can delineate
tumor tissue in vivo.18,19 [68Ga(HP3-RGD3)], prepared using
simple radiolabeling procedures, can image synovial inﬂamma-
tion in mice with induced rheumatoid arthritis, distinguishing
severely arthritic joints from disease-free joints. Few data are
available on αvβ3 integrin targeted radiotracers for rheumatoid
arthritis,55,56 and the mouse models employed in previously
published studies diﬀer from the model utilized here. However,
we note that [68Ga(HP3-RGD3)] uptake in severely arthritic
synovial joints of mice in a serum transfer-induced arthritis
model (0.26 ± 0.02%ID in wrists and 0.68 ± 0.18%ID in ankles
1 h PI) is comparable to 111In-DOTA-E(RGDfK)2 uptake in
mice in a collagen-induced arthritis model (0.2 ± 0.1%ID in
arthritic joints at 1 h PI).55
Rheumatoid arthritis is currently diagnosed using informa-
tion from physical examination (signs and symptoms), blood
tests, X-rays, and MRI. Ideally, it is diagnosed early so that
treatment that slows or halts disease progression can begin.
Current early diagnostic methods detect anatomical changes in
patients’ joints and so arthritic sites in patients that are not
symptomatic or visually identiﬁable are missed.67,68 PET/CT
imaging of αvβ3 integrin expression using kit-based radiophar-
maceuticals could provide whole-body diagnosis at early stages
of disease before the manifestation of debilitating symptoms, as
well as monitor patient response throughout treatment,
providing greater eﬀectiveness of treatment at early stages of
disease. Such radiotracers could also be used to predict whether
an individual patient will respond to a particular molecular
therapeutic, based on the presence of a therapeutic receptor
target. The availability of 68Ga from a benchtop generator,
coupled with a chelator conjugate that enables one-step, kit-
based syntheses, which are not readily achievable with other
chelators, brings about the possibility of widely available whole
body PET molecular imaging of rheumatoid arthritis without
the need for a local cyclotron or automated radiosynthesis
equipment.
■ EXPERIMENTAL SECTION
Materials and Instrumentation. Chemicals and reagents
were obtained from Sigma-Aldrich (Dorset, UK) unless
otherwise speciﬁed. High-performance liquid chromatography
(HPLC) analysis was carried out using an Agilent 1200 LC
system with in-line UV and gamma detection (Flow-Count,
LabLogic). NMR spectra were acquired on either a Bruker
Avance 400 or 700 spectrometer (Bruker UK Limited,
Coventry, UK). Spectra were referenced to residual solvent
signals. Mass spectra were recorded in the positive ion mode on
an Agilent 6510 Q-TOF LC/MS mass spectrometer coupled to
an Agilent 1200 LC system (Agilent, Palo Alto, CA). Data were
acquired and reference mass-corrected via a dual-spray
electrospray ionization source, using the factory-deﬁned
calibration procedure. Analytical reverse-phase LCMS and
radio-LCMS traces were acquired using an Agilent Eclipse
XDB-C18 column (4.6 × 150 mm, 5 μm). Instant thin layer
chromatography strips (ITLC-SG) were obtained from Varian
Medical Systems UK, Ltd. (Crawley, UK), and ITLC strips
were visualized using a Raytest Rita-Star TLC scanner.
Semipreparative reverse-phase HPLC was conducted using an
Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 μm)
coupled to an Agilent 1200 LC system, with a 3 mL min−1 ﬂow
rate and UV spectroscopic detection at 220 nm. Mobile phase
A contained water with 0.2% TFA and mobile phase B
contained acetonitrile with 0.2% TFA. All methods started with
100% A at 0 min. For method 1, the concentration of B
increased at a rate of 2% min−1; for method 2, the
concentration of B increased at a rate of 1% min−1; and for
method 3, the concentration of B increased at a rate of 0.5%
min−1. Analytical reverse-phase HPLC and radio-HPLC traces
were acquired using two diﬀerent instruments: (1) an Agilent
1200 LC system and an Agilent Zorbax Eclipse XDB-C18
column (4.6 × 150 mm, 5 μm) with a 0.25−1 mL min−1 ﬂow
rate and UV spectroscopic detection at either 214 or 220 nm.
The radio-HPLC was coupled to a LabLogic Flow-Count
detector with a sodium iodide probe (B-FC-3200). Aliquots
(10−200 μL) of each radiolabeled sample were injected onto
the column. Mobile phase A contained water with 0.1% TFA
and mobile phase B contained acetonitrile with 0.1% TFA. For
method 4, ﬂow rate was 1 mL min−1, the concentration of B
increased at a rate of 5% min−1, with 100% A at 0 min, and
100% B at 20 min. For method 5, ﬂow rate was 0.25 mL min−1,
the concentration of B increased at a rate of 2% min−1, with
100% A at 0−5 min, and 100% B at 55 min. (2) An Agilent
Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5 μm) with a
1 mL min−1 ﬂow rate and UV spectroscopic detection at either
214 or 220 nm coupled to a Shimadzu HPLC consisting of a
SCL-10AVP system controller, a SIL-10ADVP autoinjector, a
LC-10 ATVP solvent delivery unit, a FCV-10AL control valve,
a DGU-14A degasser, and a SPD-10AVP UV detector. This was
coupled to a radiation detector consisting of an Ortec model
276 Photomultiplier Base with Preampliﬁer, Ampliﬁer, BIAS
supply, and SCA and a Bicron 1 M 11.2 Photomultiplier Tube.
For method 6, the concentration of B increased at a rate of
6.67% min−1, with 100% A at 0 min, and 80% B at 12 min. For
initial radiolabeling and characterization studies that utilized
<400 MBq, an Eckert and Ziegler 68Ge/68Ga generator (Berlin,
Germany) was used. For biodistribution studies, and experi-
ments that utilized >600 MBq 68Ga, an iThemba Laboratories
1.8 GBq 68Ge/68Ga generator (IDB Holland BV, Netherlands)
was used.
Tricarboxylate 1,17 hydroxypyridinone 2,69 SCN-HP3, and
HP3-RGD were synthesized as previously described.
18 The
cyclic peptide c(RGDfK) was provided by Peptide Synthetics
(Fareham, UK).
Compound 4. A solution of tricarboxylate 1 (18 mg, 40
μmol), hydroxypyridinone 2 (170 mg, 160 μmol), HATU (60
mg, 158 μmol), and diisopropylethylamine (30 μL) in DMF
(2−5 mL) was heated in a microwave reactor (120 °C, 300 W,
30 min), after which the reaction solution was evaporated to
dryness under reduced pressure. The residue was applied to a
silica column, and eluted initially with methanol/chloroform
(1:4), followed by methanol/chloroform/40% ammonium
hydroxide (10:40:1). Fractions containing 3 (identiﬁed using
mass spectrometry) were dried over anhydrous magnesium
sulfate, ﬁltered, and evaporated to dryness. Compound 3: ESI-
MS: m/z for C195H228N26O36 + 3H
+ calc 1170.90, found
1170.90 (monoisotopic signal). Compound 3 (105 mg, 30
μmol) was added to a solution of ethanol/aqueous 5.5%
hydrazine (9:1) (5 mL), and the mixture was heated in a
microwave reactor (90−100 °C, 300 W, 30 min). The solution
was cooled in an ice bath, and acidiﬁed with concentrated
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hydrochloric acid to pH 1, ﬁltered, and evaporated to dryness.
The residue was redissolved in water/acetonitrile (2:1) and
applied to a semipreparative HPLC column. Using HPLC
method 1, 4 eluted with 44% B (22−25 min). Fractions
containing the desired product were lyophilized. Yield = 55 mg,
40% yield (based on tricarboxylate 1). 1H NMR (CD3OD, 400
MHz): δ 1.84 (m, 6H), 1.91 (m, 18H), 2.05 (m, 6H), 2.14 (m,
18H), 2.30 (t, J = 7.2, 6H), 2.53 (s, 27H), 2.56 (broad, 2H),
3.10 (t, J = 6.1, 2H), 3.34 (broad, 6H), 3.78 (s, 27H), 4.56 (s,
18H), 5.17 (s, 18H), 6.95 (s, 9H), 7.34 (m, 27H), 7.43 (m,
18H). 13C NMR (CD3OD, 100 MHz): δ 21.2, 31.2, 30.9, 36.5,
37.3, 37.4, 38.9, 59.0, 75.7, 117.5, 129.70, 129.71, 130.1, 137.9,
146.0, 146.4, 152.9, 170.1, 171.5, 173.2, 175.4, 175.5,
quaternary carbons of tripodal scaﬀold obscured by CD3OD
peaks. ESI-MS: m/z for C187H226N26O34 + 3H
+ calc 1127.57,
found 1127.57 (monoisotopic signal).
SCN-HP9. An excess of p-phenylene diisothiocyanate (22
mg) and diisopropylethylamine (20 μL) in DMF (0.3 mL)
were added to a solution of 4 (15 mg, 4.4 μmol) in DMF (0.5−
1 mL). The reaction solution was agitated, and after 5−10 min,
applied to a semipreparative HPLC column. Using HPLC
method 1, product 5 eluted with 48% B (24−25 min).
Fractions containing compound 5 were lyophilized. Compound
5: yield = 7 mg, 45%. 1H NMR (CD3OD, 400 MHz): δ 1.86
(m, 6H), 1.90 (m, 18H), 2.07 (m, 6H), 2.14 (m, 18H), 2.28 (t,
J = 6.7, 6H), 2.46 (t, J = 6.1, 2H), 2.55 (s, 27H), 3.31
(presumed 6H, under CHD2OD signal), 3.76 (broad, 2H), 3.80
(s, 27H), 4.58 (s, 18H), 5.18 (s, 18H), 7.00 (s, 9H), 7.14 (d, J =
9.0, 2H) 7.33 (m, 27H), 7.42 (m, 18H), 7.45 (under peak at
7.42, 2H). ESI-MS: m/z for C195H230N28O34S2 + 4H
+ calc
893.92, found 893.92 (monoisotopic signal). A solution of
chilled boron trichloride in dichloromethane (5 mL, 1 M) was
added to a sealed vial containing compound 5 (7 mg, 2 μmol),
and the reaction was stirred at ambient temperature for 1 h.
The reaction vial was then cooled in an ice bath, and methanol
(5−10 mL) was added dropwise to the ﬂask. The reaction
solution was evaporated to near dryness under reduced
pressure, and acetone (50 mL) was added to the residue,
resulting in a ﬂocculant white precipitate. This suspension was
transferred to a 50 mL centrifuge tube, and the mixture
centrifuged at 3000 rpm for 10 min. After this, the supernatant
was decanted and discarded, acetone added (50 mL), the
suspension agitated, and centrifuged again for 10 min. This
process of washing with acetone was repeated again. Finally, the
product was dissolved in water/acetonitrile (50/50), ﬁltered,
frozen, and lyophilized. The residue was applied to a
semipreparative HPLC column. Using HPLC method 2,
SCN-HP9 eluted with 35% B (35−36 min). Fractions
containing the desired product were lyophilized. Yield
(triﬂuoroacetate salt) = 3 mg, 30−40%. 1H NMR (CD3OD,
700 MHz): δ 1.93 (t, J = 7.5, 6H), 1.96 (t, J = 7.5 18H), 2.15 (t,
J = 7.5, 6H), 2.22 (t, J = 7.5, 18H), 2.33 (t, J = 6.3, 6H), 2.52
(broad, 2H), 2.57 (s, 27H), 3.35 (broad, 6H), 3.79 (broad,
2H), 3.92 (s, 27H), 4.70 (s, 18H), 6.93 (s, 9H), 7.20 (d,
splitting = 8.7, 2H), 7.48 (d, splitting = 8.7, 2H). 13C NMR
(CD3OD, 175 MHz): δ 19.7, 29.3, 29.7, 34.9, 35.8, 36.1, 37.9,
57.5, 112.8, 123.9, 125.7, 127.0, 135.1, 137.8, 144.0, 148.9,
161.9, 172.0, 174.3, 174.9, 175.0, 180.6, quaternary carbons of
tripodal scaﬀold obscured by CD3OD peaks. ESI-MS: m/z for
C132H176N28O34S2 + 4H
+ calc 691.32, found 691.32 (mono-
isotopic signal).
RGD3. A solution of DMF (5 mL) containing tricarboxylate
1 (100 mg, 220 μmol), diisopropylcarbodiimide (10 equiv), N-
hydroxysuccinimide (4 equiv), and diisopropylethylamine (4
equiv) was stirred for 16 h, after which it was ﬁltered, and the
ﬁltrate applied to a semipreparative HPLC column. Using
HPLC method 2, product 6 eluted with 38% B (38−42 min),
and fractions containing the desired compound were
lyophilized. Compound 6: isolated yield = 50 mg, 30%. 1H
NMR (CDCl3, 400 MHz): δ 2.22 (t, J = 7.4, 6H), 2.50 (t, J =
7.0, 2H), 2.77 (s, 12H), 2.59 (t, J = 7.4, 6H), 3.92 (t, J = 7.0,
2H), 7.67 (q, splitting = 3.0, 5.5, 2H), 7.79 (q, splitting = 3.0,
5.5, 2H). 13C NMR (CDCl3, 100 MHz): δ 25.5, 25.8, 28.6,
34.0, 34.6, 50.0, 123.3,132.2, 134.0, 168.3, 168.5, 169.6. ESI-
MS: m/z for C33H33N5O15 + H
+ calc 740.20, found 740.21.
Activated triester 6 (5 mg, 7 μmol) was added to a solution of
c(RGDfK) (20 mg, 24 μmol) and diisopropylethylamine (5
μL) in dimethylformamide (0.1−0.5 mL), and the solution was
stirred for 10 min reaction at ambient temperature. After this
time, the solution was applied to a semipreparative HPLC
column. Using HPLC method 2, compound 7 eluted with 32%
B (32 min). Fractions containing the desired product were
lyophilized. Compound 7: yield of triﬂuoroacetate salt = 7.5
mg, 42%. ESI-MS: m/z for C102H141N29O27 + 2H
+ calc 1103.04,
found 1103.04 (monoisotopic signal). Finally, phthalimide-
protected compound 7 (15 mg) was added to a solution of
ethanol/aqueous 5.5% hydrazine (9:1) (5 mL), and the mixture
was heated in a microwave reactor (90−100 °C, 300 W, 30
min). The solution was then cooled in an ice bath, and acidiﬁed
with concentrated hydrochloric acid to pH 1, ﬁltered, and
lyophilized. The solution was redissolved in deionized water
and applied to a semipreparative HPLC column. Using HPLC
method 2, RGD3 eluted with 28% B (28 min). Fractions
containing RGD3 were lyophilized. Yield: 6 mg, 40%. ESI-MS:
m/z for C102H141N29O27 + 4H
+ calc 519.52, found 519.52
(monoisotopic signal); HPLC: 220 nm, RT = 7.90 min, >97%
purity (HPLC method 4).
Synthesis of RGD Conjugates. RGD3 was dissolved in
dimethyl sulfoxide (100−300 μL) and added to a solution of
either SCN-HP3 or SCN-HP9 in dimethyl sulfoxide (100−300
μL), and diisopropylethylamine (5−10 μL) was added. The
reaction solutions were heated in a microwave (120 °C, 300 W,
30 min) and then applied to a reverse-phase HPLC column.
Fractions containing the desired conjugate in suﬃcient purity
were combined and lyophilized. Using HPLC method 3, HP3-
RGD3 eluted with 26% solvent B (52 min) and HP9-RGD3
eluted with 25% solvent B (51 min). Isolated yields = 30−40%.
HP3-RGD3: ESI-MS: m/z for C139H195N39O35S2 + 5H
+ calc
607.89, found 607.89 (monoisotopic signal); HPLC: 220 nm,
RT = 8.02 min, >99% purity (HPLC method 4). HP9-RGD3:
ESI-MS: m/z for C226H315N57O59S2 + 6H
+ calc 806.89, found
806.89 (monoisotopic signal); HPLC: 220 nm, RT = 7.77 min,
>99% purity (HPLC method 4).
Complexation with 68Ga3+ and natGa3+. Initial radio-
labeling experiments utilized an Eckert and Ziegler 68Ge/68Ga
generator. Aqueous HCl solution (0.1 M, 5 mL) was passed
through the generator and the eluate was fractionated (5 × 1
mL). The second fraction (1 mL, containing 90−100 MBq
68Ga) was added directly to an ethanol/water solution (50%/
50%, 50−100 μL) of either HP3-RGD (25 μg, 12 nmol), HP3-
RGD3 (50 μg, 13 nmol), or HP9-RGD3 (25 μg, 4 nmol),
immediately followed by a solution of ammonium acetate (1 M,
300 μL). This solution was immediately applied to an analytical
reverse-phase C18 HPLC column. [68Ga(HP3-RGD)]: radio-
chemical yield >99% (HPLC), HPLC: RT = 8.38 min (HPLC
method 4). [68Ga(HP3-RGD3)]: radiochemical yield >99%
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(HPLC), HPLC: RT = 8.37 min (HPLC method 4).
[68Ga(HP9-RGD3)]: radiochemical yield >99% (HPLC),
HPLC: RT = 8.32 min (HPLC method 4). For [68Ga(HP3-
RGD)] and [68Ga(HP3-RGD3)], speciﬁc activity at point of
synthesis = 8−9 MBq nmol−1 conjugate and for [68Ga(HP9-
RGD3)], speciﬁc activity = 24−27 MBq nmol−1.
The nonradioactive analogues, [natGa(HP3-RGD)], [
natGa-
(HP3-RGD3)], and [
natGa3(HP9-RGD3)], were also prepared.
An aqueous solution of Ga(NO3)3 (2 mg mL
−1, 5 μL, 30−40
nmol, excess) was added to HP3-RGD (25 μg, 12 nmol), HP3-
RGD3 (50 μg, 13 nmol), or HP9-RGD3 (25 μg, 4 nmol)
dissolved in an ethanol/water solution (50%/50%, 50−100
μL). The solutions were applied to an analytical reverse-phase
C18 HPLC column and subjected to LCMS analysis.
[natGa(HP3-RGD)]: HPLC RT = 8.93 min (HPLC method
4); MS C72H94N19O17S2Ga + 2H
+, observed monoisotopic peak
= 815.80, calculated = 815.80 (monoisotopic signal); [natGa-
(HP3-RGD3)]: HPLC RT = 9.05 min (HPLC method 4); MS
C139H192N39O25S2Ga + 3H
+, observed monoisotopic peak
=1034.45, calculated 1034.45 (monoisotopic signal);
[natGa3(HP9-RGD3)]: HPLC RT = 8.88 min (HPLC method
4); MS C226H306N57O59S2Ga3 + 4H
+, observed monoisotopic
peak = 1259.26, calculated 1259.25 (monoisotopic signal). For
more detailed LCMS analysis of HP9-RGD3, HP9-RGD3 was
titrated with 0, 1, 2, and 3 mol equiv of Ga(NO3)3, prior to
analysis using LCMS (HPLC method 5).
For biodistribution with U87MG tumor bearing mice, 68Ga
eluate from an iThemba Lab generator was preconditioned as
previously described.50 Brieﬂy, a cation exchange cartridge
containing AG 50Wx4 resin (50 mg) was conditioned by
passing through aqueous HCl solution (4 M, 1 mL) and
deionized water (1 mL) sequentially. To elute the 68Ge/68Ga
generator, aqueous HCl solution (0.4 M, 5 mL) was passed
through the generator and transferred directly onto the cation
exchange cartridge. The cartridge was dried with air (1 mL),
washed with 0.15 M HCl in water/ethanol (20%/80%), and
again dried with air (1 mL). A solution of 0.9 M HCl in water/
ethanol (200 μL, 10%/90%) was used to elute 68Ga (800−1000
MBq), which was diluted to a volume of 1 mL with deionized
water. Lyophilized peptide conjugate (triﬂuoroacetate salt)
HP3-RGD (25 μg, 12 nmol), HP3-RGD3 (50 μg, 13 nmol), or
HP9-RGD3 (25 μg, 4 nmol)dissolved in 20−40 μL of water/
ethanol (50%/50%) was added to the solution containing 68Ga,
immediately followed by a solution of ammonium acetate (2 M,
400 μL) and 0.9% saline (1100 μL). An aliquot for ITLC
analysis was immediately applied to an ITLC-SG plate. The
ITLC-SG plate was developed using an aqueous citrate buﬀer
(0.1 M, pH 5.5) mobile phase. [68Ga(HP3-RGD)], [
68Ga(HP3-
RGD3)], and [
68Ga(HP9-RGD3)]: Rf < 0.1; [
68Ga(citrate)2]
3−:
Rf > 0.8. [
68Ga(HP3-RGD)]: radiochemical yield > 95%
(ITLC). HPLC (method 6): RT = 9.78 min; [68Ga(HP3-
RGD3)]: radiochemical yield > 95% (ITLC), HPLC: RT = 9.54
min; [68Ga(HP9-RGD9)]: radiochemical yield > 95% (ITLC),
HPLC: RT = 9.50 min.
Log POCT/PBS Determination. A solution containing
68Ga-
conjugate (50 μL, synthesized using eluate from an Eckert and
Ziegler generator as described above) was added to 550 μL of
octanol and 500 μL of aqueous phosphate buﬀered saline
solution. The mixture was agitated using a vortex, and the
phases separated by centrifugation (1000 rpm, 2 min). Aliquots
from each phase were counted for radioactivity in a gamma
counter. The experiment was repeated four times.
Determination of IC50. The relative aﬃnity of [
natGa(HP3-
RGD)], [natGa(HP3-RGD3)], [
natGa3(HP9-RGD3)], and c-
(RGDfK) for integrin αvβ3 was determined in a solid-phase
competitive binding assay18 with 125I-echistatin (PerkinElmer,
Boston). In brief, wells of a 96 well plate were coated with
integrin αvβ3 (150 ng mL
−1) in coating buﬀer (100 μL, 25 mM
Tris HCl pH 7.4, 150 mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2,
and 1 mM MnCl2) overnight at 4 °C. Wells were then washed
twice in binding buﬀer (coating buﬀer containing 0.1% bovine
serum albumin (w/v) (BSA)) before being incubated for 2 h at
room temperature with blocking buﬀer (coating buﬀer
containing 1% BSA (w/v)). After a further two washes in
binding buﬀer, 125I-echistatin (0.5 kBq) and either [natGa(HP3-
RGD)], [natGa(HP3-RGD3)], [
natGa3(HP9-RGD3)] or c-
(RGDfK) were added simultaneously (to a total volume of
100 μL, and a conjugate/c(RGDfK) concentration of 10000
nM to 0.001 nM) for 1 h at room temperature, before being
washed twice as before. Finally, the amount of activity bound to
the wells via integrin αvβ3 was counted using a Wallac 1282
Compugamma Universal Gamma Counter. Measurements at
each concentration for each compound were obtained in
sextuplicate. IC50 values were calculated using a nonlinear
regression model (Binding/Saturation, one site−total) in
GraphPad Prism 5.04.
PET Scanning and Biodistribution of U87MG Tumor
Bearing Animals. All animal experiments with U87MG tumor
bearing animals were performed with approval from the Peter
MacCallum animal experimentation ethics committee. Six- to
eight-week-old female Balb/c nude mice (Animal Resources
Centre, Western Australia) were implanted subcutaneously on
the right ﬂank with 4 million U87MG cells. Once the tumors
reached a volume >250 mm3 (two to three weeks) the animals
were injected intravenously with 13−30 MBq of [68Ga(HP3-
RGD)] (1 μg of conjugate), [68Ga(HP3-RGD3)] (2 μg of
conjugate), and [68Ga(HP9-RGD3)] (1 μg of conjugate) (100
μL of solutions described above). At 1 and 2 h, the animals
were anaesthetized and imaged on a Philips MOSAIC small
animal PET scanner for 10 min each. For blocking studies,
animals were coinjected with c(RGDfK) peptide (400 μg),
anaesthetized at 1 h, and imaged for 10 min each. The images
were reconstructed using a 3D RAMLA algorithm, and
radiotracer uptake was determined by ex vivo tissue counting
as described previously.70 On completion of the scan animals
were euthanized by cervical dislocation and tissues harvested,
weighed, and radioactivity counted using a gamma counter
(Biomedex). Conﬁdence intervals and p values were calculated
using a two-tailed t-test in GraphPad Prism 5.04.
PET/CT Scanning and Biodistribution of Animals with
Induced Rheumatoid Arthritis. All animal experiments on
mice with induced rheumatoid arthritis complied with the
Animals (Scientiﬁc Procedures) Act (UK 1986) and Home
Oﬃce (UK) guidelines. A K/BxN serum transfer model of
arthritis was utilized in these experiments, and serum was
produced as previously reported.59,60 Wild type C57Bl/6 male
6−8-week-old mice (Charles River) were injected with 150 μL
arthritogenic serum (intraperitoneally) on days 0 and 2. The
arthritic serum was either diluted 2-fold with PBS (to induce
severe arthritis) or 8-fold with PBS (to induce mild arthritis).
PBS alone was also injected into a third group to assess uptake
in nonarthritic mice. Disease severity was evaluated in mice on
days 0, 2 and 8 post-injection, by measuring weight loss,
thickness of swollen paws, using microcalipers (Kroeplin), and
visual clinical scoring on a scale of 0−3 per paw added for a
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total score out of 12 per animal. On day 8, animals from the
control, the mild arthritis and severe arthritis groups (n = 3)
were injected intravenously with [68Ga(HP3-RGD3)] (8−14
MBq, 4 μg HP3-RGD3). A fourth group of animals (n = 3) with
severe arthritis were coadministered [68Ga(HP3-RGD3)] (8−14
MBq, 4 μg HP3-RGD3) and c(RGDfK) peptide (400 μg).
[68Ga(HP3-RGD3)] was prepared using protocols described
above for radiolabeling with an Eckert and Ziegler 68Ge/68Ga
generator. Animals were injected under isoﬂurane anesthesia,
after which they were immediately allowed to recover. One
hour post-injection, animals were culled by CO2 asphyxiation
and PET scanned using a nanoScanPET/CT (Mediso Medical
Imaging Systems, Budapest, Hungary) and organs/tissues
harvested, weighed, and radioactivity counted using a gamma
counter. PET/CT images were reconstructed using VivoQuant
(inviCRO, LLC, Boston, USA). Conﬁdence intervals and p
values were calculated using a two-tailed t-test in GraphPad
Prism 5.04.
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